
    
      This is a Phase 3, randomized, double-blind, multicenter, placebo-controlled, 6 month
      maintenance study. The study is designed to compare the efficacy and safety of daily
      dexlansoprazole MR (30 mg and 60 mg) with that of placebo, in maintaining healing of EE.
    
  